Tamra Bunn is Founder and CEO of Invernadero, Inc., a Public Benefit Corporation developing novel biotech platforms at the intersection of wound care, aging biology, and precision nutrition delivery. Her lead platform, AdaptaFusion, is a severity-graded topical burn care system with no commercial analog across any severity level, currently advancing toward NIH SBIR Phase I submission targeting NIA. Invernadero holds provisional patents across multiple platform technologies with non-provisional filings in progress. Expertise spans biopharmaceutics, biochemical engineering, aging, and biotechnology.